Novel 3,7-diheterabicyclo[3.3.1]nonanes that possess predominant class III antiarrhythmic activity in 1-4 day post infarction dog models: X-ray diffraction analysis of 3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3,7-diazabicyclo[3.3.1]nonane dihydroperchlorate

Journal of Medicinal Chemistry

Volumn 39, Issue 13, 1996, Pages 2559-2570

  Garrison, Gregory L ^a   Berlin, K Darrell ^a   Scherlag, Benjamin J ^b   Lazzara, Ralph ^b   Patterson, Eugene ^b   Fazekas, Tamas ^b   Sangiah, Subbiah ^a   Chen, Chun Lin ^a   Schubot, F D ^c   Van Der Helm, Dick ^c  

^a OKLAHOMA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [4 (1H IMIDAZOL 1 YL)BENZOYL] 7 ISOPROPYL 3,7 DIAZABICYCLO[3.3.1]NONANE; ANTIARRHYTHMIC AGENT; BICYCLO[3.3.1]NONANE DERIVATIVE; IMIDAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; DOG; DRUG CONFORMATION; DRUG EFFECT; DRUG SCREENING; HEART ARRHYTHMIA; HEART INFARCTION; HEART VENTRICLE TACHYCARDIA; NONHUMAN; X RAY CRYSTALLOGRAPHY; X RAY DIFFRACTION;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; BLOOD PRESSURE; CRYSTALLOGRAPHY, X-RAY; DOGS; ELECTROPHYSIOLOGY; HEART RATE; IMIDAZOLES; LIDOCAINE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; MYOCARDIAL INFARCTION; TACHYCARDIA, VENTRICULAR;

EID: 0029892710     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm950772j     Document Type: Article

References (47)

1. Olshausen, K. V.; Witt, T.; Pop, T.; Treese, N.; Sethge, K.; Meyer, J. Sudden Cardiac Death While Wearing a Holter Monitor. Am. J. Cardiol. 1991, 67, 381-386.
2. Rosen, M. R.; Janse, M. J.; Myerburg, R. J. Arrhythmias Induced by Coronary Artery Occlusions. What Are the Electrophysiological Mechanisms? In Life-Threatening Arrhythmias During Ischemia and Infarction; Hearse, D., Manning, A., Janse, M., Eds.; Raven Press: New York, 1987; pp 11-47.
3. (a) Vaughan Williams, E. M. Significance of Classifying Anti-arrhythmic Actions Since the CAST. J. Clin. Pharmacol. 1991, 31, 123-135.
4. (b) Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian Gambit: A New Approach to the Classification of Anti-arrhythmic Drugs Based on Their Actions on Arrhythmogenic Mechanisms. Circulation 1991, 84 (4), 1831-1851.
5. Butera, J. A.; Spinelli, W.; Anantharaman, V.; Marcopulos, N.; Parsons, R. W.; Moubarak, I. F.; Cullinan, C.; Baglui, J. F. Synthesis and Selective Class III Antiarrhythmic Activity of Novel N-Heteroalkyl Substituted 1-(Aryloxy)-2-Propanolamine and Related Propylamine Derivatives. J. Med. Chem. 1991, 34, 3212-3228.
6. Colatsky, T. J. Modulation of Cardiac Repolarization Currents by Antiarrhythmic Drugs in Cardiac Electrophysiology: A Textbook; Rosen, M. R., Janse, M. J., Wit, A. L., Eds.; Futura Publishing Co.: Mount Kisco, NY, 1990; pp 1043-1062.
7. (a) Bailey, B. R., III; Berlin, K. D.; Holt, E. M.; Scherlag, B. J.; Lazzara, R.; Brachmann, J.; van der Helm, D.; Powell, D. R.; Pantaleo, N.; Ruentiz, P. C. Synthesis, Conformational Analysis, and Antiarrhythmic Properties of 7-Benzyl-3-thia-7-azabicyclo-[3.3.1]nonan-9-one, 7-Benzyl-3-thia-7-azabicyclo[3.3.1]nonane Hydroperchlorate, and 7-Benzyl-9-phenyl-3-thia-7-azabicyclo[3.3.1]-nonan-9-ol Hydroperchlorate and Derivatives: Single Crystal X-ray Diffraction Analysis and Evidence for Chair-Chair and Chair-Boat Conformers in the Solid State J. Med. Chem. 1985, 27, 758-767.
8. (b) Bailey, B. R., III. Synthesis and Conformational Analysis of Selected 7-Aza-3-thia-bicyclo[3.3.1]nonanes and Derivatives. Ph.D. Dissertation, Oklahoma State University, 1983.
9. (c) Zisman, S. A.; Berlin, K. D.; Scherlag, B. The Preparation of Amide Derivatives of 3-Azabicyclo-[3.3.1]non-anes as New Potential Antiarrhythmic Agents. Org. Prep. Proc. Int. 1990, 22(2), 255-264.
10. (d) Patterson, E.; Scherlag, B. J.; Berlin, K. D.; Lazzara, R. Electrophysiologic Actions of BRB-I-28 in Ischemically Injured canine Myocardium. J. Cardiovasc. Pharmacol. 1993, 21, 637-646.
11. (e) Fazekas, T.; Mabo, P.; Berlin, K. D.; Garrison, G. L.; Patterson, E.; Scherlag, B. J.; Lazzara, R. A Lidokainés a BRB-I-28 Összehasonlíto Szívelektrofiziológiai Vizsgálata Experimentális Szívizom Infarktusban. Cardiol. Hung. 1993, 22, 17-21.
12. (f) Chen, C.-L.; Sangiah, S.; Berlin, K. D.; Scherlag, B. J.; Patterson, E.; Lazzara, R. brb-I-28-a Review of a Novel Class Ib Antiarrhythmic Agent. Cardiovasc. Drug Rev. 1994, 12, 237-253.
13. (g) Smith, G. S.; Thompson, M. D.; Berlin, K. D.; Holt, E. M.; Scherlag, B. J.; Patterson, E.; Lazzara, R. A. Study of the Synthesis and Antiarrhythmic Properties of selected 3,7-diheterabicyclo[3.3.1]nonanes with substituents at the 2,4-positions and at the 9-position. Eur. J. Med. Chem. 1990, 25, 1-8. For a review of DHBCNs, see:
14. (h) Jeyaraman, R.; Avila, S. Chemistry of 3-Azabicydo[3.3.1]nonanes. Chem. Rev. 1981, 81, 149-174.
15. ++-ATPase Activities and Contractile Force. Res. Commun. Chem. Path. Pharmacol. 1992, 78, 3-16.
16. Bristol, J. A., Ed. Cardiovascular Drugs; John Wiley and Sons: New York, 1986.
17. Lumma, W. C., Jr.; Wohl, R. A.; Davey, D. D.; Argentieri, T. M.; De Veta, R. J.; Gomez, R. P.; Jain, V. K.; Morgan, T. K.; Reiser, H. J.; Sullivan, M. E.; Wiggins, J.; Wong, S. S. Rational Design of 4-[(Methylsulfonyl)amino]benzamides as Class III Antiarrhythmic Agents. J. Med. Chem. 1987, 30, 755-762.
18. + Current Blockers. Eur. J. Pharmacol. 1991, 102, 13-18.
19. (a) Echt, D. S.; Liebson, P. R.; Mitchell, L. B.; Peters, R. W.; Obias-Manno, D.; Barker, A. H.; Arensburg, D.; Baker, A.; Friedman, L.; Greene, H. L.; Huther, M. L.; Richardson, D. W.; and the CAST Investigators. Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo. The Cardiac Arrhythmia Suppression Trial. N. Engl. J. Med. 1991, 324, 781-788.
20. (b) Green, H. L. and the CAST Investigators. The Cardiac Arrhythmia Suppression Trial: First CAST, then CAST II. J. Am. Coll. Cardiol. 1993, 19, 894-898.
21. (c) The CASCADE Investigators. The Cascade Study. Randomized Antiarrhythmic Drug Therapy in Survivors of Cardiac Arrest in Seattle. Am. J. Cardiol. 1993, 72, 280-287. For an overall evaluation of risks and benefits of antiarrhythmic therapy, see:
22. (d) Mason, J. W. A Comparison of Seven Antiarrhythmic Drugs in Patients With Ventricular Tachyarrhythmias. N. Engl. J. Med. 1993, 329, 452-458.
23. (e) Roden, D. M. Risks and Benefits of Antiarrhythmic Therapy. Drug Ther. 1994, 331, 785-791.
24. Doroshuk, C. M.; Sullivan, M. E. Synergistic Antiarrhythmic Action of Propranolol and Sematilide in Experimental Myocardial Infarction. Pharmcologist 1988, 30, 177-181.
25. (a) Lis, R.; Morgan, T. K., Jr.; Marisca, A. J.; Gomez, R. P.; Lind, J. M.; Davey, D. D.; Phillips, G. B.; Sullivan, M. E. Synthesis of Novel (Aryloxy)propanolamines and Related Compounds Possessing Both Class II and Class III Antiarrhythmic Activity. J. Med. Chem. 1990, 33, 2883-2891. It should be pointed out that cardiovascular properties of sotalol were reviewed recently in a favorable manner, but an Addendum at the end of the review delineated the preliminary results of the SWORD study to be published and which indicate mortality was higher with d-sotaol than with the placebo; see:
26. (b) Claudel, J. P.; Touboul, P. Sotalol: From "Just Another Beta Blocker" to "The Prototype of Class III Anti-dysrhythmic Compound". PACE 1995, 18 [Pt. I], 451-467.
27. (a) Berlin, K. D.; Scherlag, B. J.; Clarke, C. R.; Otiv, S. R.; Zisman, S. A.; Sangiah, S.; Mulekar, S. V. Salts of 3-Azabicyclo-[3.3.1]nonanes As Potential Antiarrhythmic Agents, and Precursors Thereof. U.S. Patent 5,084,572, 1992; Chem. Abstr. 1991, 115, 114550c.
28. (b) Thompson, M. D.; Smith, G. S.; Berlin, K. D.; Holt, E. M.; Scherlag, B. J.; van der Helm, D.; Muchmore, S. W.; Fidelis, K. A. Synthesis and Antiarrhythmic Properties of Novel 3-Selena-7-azabicyclo[3.3.1]nonanes and Derivatives. Single-Crystal X-Ray Diffraction Analysis of 7-Benzyl-3-selena-7-azabicyclo[3.3.1]-nonan-9-one and 7-Benzyl-3-selena-7-azabicyclo-[3.3.1]nonane Hydroperchlorate. J. Med. Chem. 1987, 30, 780-788.
29. (c) Reunitz, P, C.; Mokler, C. M. Antiarrhythmic Activity of Some N-Alkylbispidinebenzamides. J. Med. Chem. 1979, 22, 1142-1146.
30. (a) Fazekas, T.; Scherlag, B. J.; Mabo, P.; Berlin, K. D.; Garrison, G. L.; Chen, C. L.; Sangiah, S.; Patterson, E.; Lazzara, R. The Comparative Antiarrhythmic and Proarrhythmic Activity of a 3,7-Diheterabicyclo[3.3.1]nonane, BRB-I-28, and Lidocaine in the 1-4 Day-Old Infarcted Dog Heart. Acta Physiol. Hung. 1993, 81, 297-307.
31. (b) Fazekas, T.; Scherlag, B. J.; Mabo, P.; Patterson, E.; Berlin, K. D.; Garrison, G. L. Egy új Refrakter Periódust Megnyújto Antiaritmiás Vegyület, A GLG-V-13 Szívelektrofiziológiai Jellemzése. Cardiol. Hung. 1993, 22, 9-15.
32. (c) Fazekas, T.; Carlsson, L.; Scherlag, B. J.; Mabo, P.; Poty, H.; Palmer, M.; Patterson, E.; Berlin, K. D.; Garrison, G. L.; Lazzara, R. Electrophysiological and Inotropic Characterization of a Novel Class III Antiarrhythmic Agent, GLG-V-13, in The Guinea-pig Heart, Rabbit and Canine Heart. J. Cardiovasc. Pharmacol., in press.
33. (a) Smith, G. S.; Berlin, K. D.; Zisman, S. A.; Holt, E. M.; Green, V. A.; van der Helm, D. The Mannich Condensation With 1-Hetera-4-cyclohexanones. The Novel Formation of 7-Benzyl-3-hetera-7-aza-bicyclo[3.3.1]nonan-9-ones, 3,6-Dibenzylhexahydro-8a-methoxy-5H-4a,8-(methanoheteramethano)-2H-pyrido-[3,4- e]-1,3-oxazines, and 2,4,10,12-Tetrabenxyl-2,4,10,12-tetraaza-15-heteradispiro[5.1.5.3]hexadecan-7- ones. Single Crystal X-Ray Diffraction Analyses of 3,6-Dibenzylhexa-hydro-8a-methoxy-5H-4a,8-(methanothiomethano)-2H-pyrido[3,4-e]- 1,3-oxazine and 2,4,-10,12-Tetraaza-15-thiadispiro[5.1.5.3]hexadecan-7-one. Phosphorus Sulfur 1988, 39, 91-111.
34. (b) Bailey, B. R., III; Berlin, K. D.; Holt, E. M. Isolation and Single Crystal X-Ray Diffraction Analysis of N-Benzyl-3-thia-7-azabicyclo[3.3.1]nonan-9,9-diol Perchlorate. A Novel Hydrate Formed From Reaction of N-Benzyl-3-thia-7-azabicyclo[3.3.1]nonan-9-one with Perchloric Acid. Phosphorus Sulfur 1984, 20, 131-137.
35. Dobler, M.; Dunitz, J. D. Die Konformation des Bicyclo[3.3.1]-nonan-Systems. I. Strukturanalyse des 3-Azabicyclo[3.3.1]nonanhydrobromids. (Structural Analyses of 3-Azabicyclo[3.3.1]nonane Hydrobromides.) Helv. Chim. Acta 1964, 47, 695-704.
36. Pinkerton, J. M. H.; Steinrauf, L. K. The Crystal and Molecular Structure of the Alkaloid 7-Hydroxy-β-isosparteine Perchlorate. J. Org. Chem. 1967, 32, 1828-1832.
37. Skrzypczak-Jankun, E.; Kaluski, Z. (-)-Lupanine Hydrochloride Dihydrate. Acta Crystallogr. 1978, B34, 2651-2653.
38. Maluszynska, H.; Hoser, A.; Kaluski, Z. [Crystal Structure of] (+)-Lupanine Perchlorate Monhydrate. Acta Crystallogr. 1979, B35, 970-973.
39. Hoser, A.; Katrusiak, A.; Kaluski, Z.; Perkowska, A. 15-Oxosparteine Perchlorate Hemihydrate. Acta Crystallogr. 1981, B37, 281-284.
40. Maluszynska, H.; Okaya, Y. 2-Phenylsparteine N(16)-Oxide Monoperchlorate. Acta Crystallogr. 1977, B33, 3889-3891.
41. Freeman, H. C.; Huq, F.; Rosalky, J. M.; Taylor, I. F., Jr. The Crystal and Molecular Structure of Imidazolium Sulphate Dihydrate. Acta Crystallogr. 1975, B31, 2833-2837.
42. Luger, P.; Ruban, G. The Crystal and Molecular Structure of 1,3-Diphenylimidazole Perchlorate. Z. Kristallogr. 1976, 143, 177-185.
43. Hussain, M. S.; Schlemper, E. O.; Fair, C. K Neutron Diffraction Study of Deuterated Imidazolium Hydrogen Maleate: An Evaluation of Isotope Effect on the Hydrogen-Bond Length. Acta Crystallogr. 1980, B36, 1104-1108.
44. Pugsley, M. K.; Walker, M. J. A.; Garrison, G. L.; Howard, P. G.; Lazzara, R.; Patterson, E.; Scherlag, B. J.; Berlin, K. D. The Cardiovascular and Antiarrhythmic Properties of a Series of Novel Sparteine Analogs. Proc. West. Pharmacol. Soc. 1992, 35, 87-91.
45. Mandel, W. J., Ed. Cardiac Arrhythmias: Their Mechanisms, Diagnosis, and Managements; J. P. Lippincott: Philadelphia, PA, 1987.
46. Sheldrick, G. M. SHELX86: Program for the Solution of Crystal Structures from X-Ray Data, University of Göttingen, Germany, 1986.
47. Sheldrick, G. M. SHELX76: Program for Crystal Structure Determination, University of Cambridge, England, 1976.